Galena Biopharma Presents Final Landmark 60-Month Results From NeuVax(TM) Phase 1/2 Trials at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium

[at noodls] – The combined SN-33 (Node Positive) and SN-34 (Node Negative) Intent-to-treat (ITT) population continued to demonstrate an excellent safety and efficacy profile….This is an abstract of the original noodl. … more

View todays social media effects on GALE

View the latest stocks trending across Twitter. Click to view dashboard

See who Galena is hiring next, click here to view